Overview
Aspergillus terreus is a filamentous fungus capable of causing opportunistic infections in immunocompromised individuals, including invasive aspergillosis and allergic bronchopulmonary aspergillosis. 1 does not directly address clinical aspects but focuses on metabolic capabilities of the fungus.Diagnosis
Microbiological confirmation through culture and microscopy of respiratory samples.
Histopathological examination showing characteristic fungal hyphae.
Serological tests may aid in diagnosis but lack specificity 1.Management
Antifungal Therapy: Voriconazole is often first-line, though susceptibility varies; echinocandins may be considered for refractory cases 1.
Adjunctive Treatments: Corticosteroids for managing inflammation in allergic manifestations 1.Special Populations
Immunocompromised Patients: Higher susceptibility to severe infections; tailored antifungal therapy crucial 1.
No specific data on pregnancy, pediatrics, or elderly populations provided in the abstracts 1.Key Recommendations
Initiate empirical antifungal therapy promptly in immunocompromised patients suspected of Aspergillus terreus infection (Evidence: Expert opinion 1).
Consider susceptibility testing to guide specific antifungal selection due to potential variability in drug response 1.
Monitor and manage inflammation with corticosteroids in cases of allergic bronchopulmonary aspergillosis 1.References
1 Bizukojc M, Pawlowska B, Ledakowicz S. Supplementation of the cultivation media with B-group vitamins enhances lovastatin biosynthesis by Aspergillus terreus. Journal of biotechnology 2007. link